Tearsheet

Bicycle Therapeutics (BCYC)

Market Price (9/4/2025): $7.2 | Market Cap: $498.6 Mil
Sector: Health Care | Industry: Biotechnology

Bicycle Therapeutics (BCYC)

Market Price (9/4/2025): $7.2
Market Cap: $498.6 Mil
Sector: Health Care
Industry: Biotechnology

Market Valuation

	9/4/25	2024	2023	2022	2021
Share Price CYE	$7.20	$14.00	$18.08	$29.60	$60.87
Market Cap CYE ($ Mil)	498.6	967.8	768.3	879.5	1,770.7
Total Debt ($ Mil)	7.2	9.5	45.0	44.3	44.3
Total Cash ($ Mil)	721.5	879.5	526.4	339.2	438.7
Enterprise Value ($ Mil)	-215.6	977.3	813.3	923.8	1,815.0
Valuation Ratios
P/S TTM	25.9	23.1	23.9	60.7	130.4
P/EBIT TTM	-2.0	-4.7	-3.7	-7.9	-23.3
P/E TTM	-2.1	-4.8	-3.6	-7.8	-22.8
Sector Ratios
P/S TTM (Sector)	3.8	4.1	4.5	4.5	6.7
P/EBIT TTM (Sector)	4.3	0.4	-1.9	-1.2	-0.4
P/E TTM (Sector)	-1.8	-2.2	-3.4	-2.2	-2.3

	9/4/25	2024	2023
Share Price CYE	$7.20	$14.00	$18.08
Market Cap CYE ($ Mil)	498.6	967.8	768.3
Total Debt ($ Mil)	7.2	9.5	45.0
Total Cash ($ Mil)	721.5	879.5	526.4
Enterprise Value ($ Mil)	-215.6	977.3	813.3
Valuation Ratios
P/S TTM	25.9	23.1	23.9
P/EBIT TTM	-2.0	-4.7	-3.7
P/E TTM	-2.1	-4.8	-3.6
Sector Ratios
P/S TTM (Sector)	3.8	4.1	4.5
P/EBIT TTM (Sector)	4.3	0.4	-1.9
P/E TTM (Sector)	-1.8	-2.2	-3.4

Stock Price
Market Cap

Stock Price Chart

Return (1Y):

Market Cap Chart

Business Description

Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics. Its lead product candidate is BT1718, a bicycle toxin conjugate (BTC), which is in Phase I/IIa clinical trials targeting tumors that express Membrane Type 1 matrix metalloprotease. The company's oncology product candidates also comprise BT5528, a BTC that is in a Phase I/II clinical trial targeting EphA2; and BT8009, which is in Phase I/II clinical trial targeting Nectin-4. Show more

Price Returns Compared

Expand for Detailed View

	2020	2021	2022	2023	2024	2025	Total [1]
Returns
BCYC Return	90%	239%	-51%	-39%	-23%	-49%	-15%
Peers Return	11%	18%	23%	15%	2%	8%	103%
S&P 500 Return	16%	27%	-19%	24%	23%	10%	100%

[1] Cumulative total returns since the beginning of 2020
[2] Peers: VRTX, ABBV, AMGN, GILD, REGN.
[3] 2025 data is for the year up to 9/3/2025 (YTD)

Latest Trefis Analyses

	Title	Topic
0	DASHBOARDS
1	BCYC Dip Buy Analysis
2	Why You Shouldn?t Be Buying Bicycle Therapeutics Stock	Buy or Fear
3	Bicycle Therapeutics (BCYC) Valuation Ratios Comparison	Financials
4	Bicycle Therapeutics Total Shareholder Return (TSR): -22.6% in 2024 and 0% 3-yr returns (below peer average)

	Title
0	ARTICLES
1	BCYC Dip Buy Analysis
2	Why You Shouldn?t Be Buying Bicycle Therapeutics Stock
3	Bicycle Therapeutics (BCYC) Valuation Ratios Comparison
4	Bicycle Therapeutics Total Shareholder Return (TSR): -22.6% in 2024 and 0% 3-yr returns (below peer average)

Recent Active Movers

1 Day Top Gainers

#	Ticker	Company	1D Rtn	YTD Rtn
1	XELA	Exela Technologies	212.4%	-95.5%
2	TKCM	Token Communities	82.8%	-64.7%
3	ANGGF	Angang Steel	61.2%	25.0%
4	BATMF	British American Tobacco Malaysia	43.4%	59.2%
5	KYSEF	Kyushu Electric Power	32.1%	32.1%
6	STTK	Shattuck Labs	26.7%	5.8%
7	KTHAF	Krung Thai Bank	24.0%	24.0%
8	SFOSF	Shanghai Fosun Pharmaceutical	23.7%	61.7%
9	INDOY	Indorama Ventures	20.9%	-5.5%
10	M	Macy's	20.7%	-1.0%

1 Day Top Losers

#	Ticker	Company	1D Rtn	YTD Rtn
1	PTLKF	PT Lippo Karawaci	-95.2%	-94.7%
2	MGAWF	Megaworld	-71.0%	-71.0%
3	PTTMF	PT Timah	-62.8%	-83.1%
4	PTJSF	PT Jasa Marga	-50.9%	-50.9%
5	UNLRF	PT Unilever Indonesia	-41.3%	-17.6%
6	DLNDY	D&L Industries	-37.5%	-30.7%
7	SUCEF	Sumitomo Osaka Cement	-37.4%	-37.4%
8	PTKFF	PT Kalbe Farma	-34.7%	-32.1%
9	SMTGF	SMA Solar Technology	-30.1%	28.4%
10	PMDKF	PT Mitra Adiperkasa	-28.6%	-48.9%

1 Week Top Gainers

#	Ticker	Company	1W Rtn	YTD Rtn
1	EAF	GrafTech International	804.0%	-47.2%
2	RLMD	Relmada Therapeutics	122.3%	182.7%
3	XELA	Exela Technologies	109.6%	-95.5%
4	PSNYW	Polestar Automotive UK	96.2%	141.5%
5	TKCM	Token Communities	82.8%	-64.7%
6	PHJMF	PT Hanjaya Mandala Sampoerna	66.7%	34.8%
7	ANGGF	Angang Steel	61.2%	25.0%
8	DTNOF	DNO	49.5%	141.9%
9	BW	Babcock & Wilcox Enterprises	48.5%	54.9%
10	MDB	MongoDB	46.0%	34.4%

1 Week Top Losers

#	Ticker	Company	1W Rtn	YTD Rtn
1	COSG	Grand Gallery	-100.0%	�
2	PTLKF	PT Lippo Karawaci	-95.2%	-94.7%
3	NXTT	Next Technology	-74.5%	-89.4%
4	SCGY	Scientific Energy	-72.7%	-26.9%
5	MGAWF	Megaworld	-71.0%	-71.0%
6	TTOO	T2 Biosystems	-67.7%	-99.0%
7	PTTMF	PT Timah	-62.8%	-83.1%
8	PIGEF	Pigeon	-62.4%	-62.4%
9	NEGG	Newegg Commerce	-53.8%	290.6%
10	PTJSF	PT Jasa Marga	-50.9%	-50.9%

1 Month Top Gainers

#	Ticker	Company	1M Rtn	YTD Rtn
1	MMEX	MMEX Resources	∞%	-50.0%
2	TAWNF	Thai Airways International	3674.5%	3400.0%
3	NOKPF	Nok Airlines	2400.0%	81.8%
4	AYRWF	Ayr Wellness	509.5%	-94.6%
5	XELA	Exela Technologies	379.0%	-95.5%
6	SRNE	Sorrento Therapeutics	233.3%	900.0%
7	PGEN	Precigen	169.9%	324.1%
8	TLS	Telos	154.7%	89.2%
9	SATS	EchoStar	142.7%	179.1%
10	RLMD	Relmada Therapeutics	139.0%	182.7%

1 Month Top Losers

#	Ticker	Company	1M Rtn	YTD Rtn
1	COSG	Grand Gallery	-100.0%	�
2	PTLKF	PT Lippo Karawaci	-95.2%	-94.7%
3	TTOO	T2 Biosystems	-94.8%	-99.0%
4	NXTT	Next Technology	-86.5%	-89.4%
5	OTRK	Ontrak	-78.2%	-96.6%
6	SCGY	Scientific Energy	-72.7%	-26.9%
7	PPCB	Propanc Biopharma	-72.1%	-79.1%
8	MGAWF	Megaworld	-71.0%	-71.0%
9	PTTMF	PT Timah	-62.8%	-83.1%
10	PIGEF	Pigeon	-62.4%	-62.4%

Recent Active Movers

1 Day Top Gainers

#	Ticker	Company	1D Rtn	YTD Rtn
1	XELA	Exela Technologies	212.4%	-95.5%
2	TKCM	Token Communities	82.8%	-64.7%
3	ANGGF	Angang Steel	61.2%	25.0%
4	BATMF	British American Tobacco Malaysia	43.4%	59.2%
5	KYSEF	Kyushu Electric Power	32.1%	32.1%
6	STTK	Shattuck Labs	26.7%	5.8%
7	KTHAF	Krung Thai Bank	24.0%	24.0%
8	SFOSF	Shanghai Fosun Pharmaceutical	23.7%	61.7%
9	INDOY	Indorama Ventures	20.9%	-5.5%
10	M	Macy's	20.7%	-1.0%

1 Day Top Losers

#	Ticker	Company	1D Rtn	YTD Rtn
1	PTLKF	PT Lippo Karawaci	-95.2%	-94.7%
2	MGAWF	Megaworld	-71.0%	-71.0%
3	PTTMF	PT Timah	-62.8%	-83.1%
4	PTJSF	PT Jasa Marga	-50.9%	-50.9%
5	UNLRF	PT Unilever Indonesia	-41.3%	-17.6%
6	DLNDY	D&L Industries	-37.5%	-30.7%
7	SUCEF	Sumitomo Osaka Cement	-37.4%	-37.4%
8	PTKFF	PT Kalbe Farma	-34.7%	-32.1%
9	SMTGF	SMA Solar Technology	-30.1%	28.4%
10	PMDKF	PT Mitra Adiperkasa	-28.6%	-48.9%

1 Week Top Gainers

#	Ticker	Company	1W Rtn	YTD Rtn
1	EAF	GrafTech International	804.0%	-47.2%
2	RLMD	Relmada Therapeutics	122.3%	182.7%
3	XELA	Exela Technologies	109.6%	-95.5%
4	PSNYW	Polestar Automotive UK	96.2%	141.5%
5	TKCM	Token Communities	82.8%	-64.7%
6	PHJMF	PT Hanjaya Mandala Sampoerna	66.7%	34.8%
7	ANGGF	Angang Steel	61.2%	25.0%
8	DTNOF	DNO	49.5%	141.9%
9	BW	Babcock & Wilcox Enterprises	48.5%	54.9%
10	MDB	MongoDB	46.0%	34.4%

1 Week Top Losers

#	Ticker	Company	1W Rtn	YTD Rtn
1	COSG	Grand Gallery	-100.0%	�
2	PTLKF	PT Lippo Karawaci	-95.2%	-94.7%
3	NXTT	Next Technology	-74.5%	-89.4%
4	SCGY	Scientific Energy	-72.7%	-26.9%
5	MGAWF	Megaworld	-71.0%	-71.0%
6	TTOO	T2 Biosystems	-67.7%	-99.0%
7	PTTMF	PT Timah	-62.8%	-83.1%
8	PIGEF	Pigeon	-62.4%	-62.4%
9	NEGG	Newegg Commerce	-53.8%	290.6%
10	PTJSF	PT Jasa Marga	-50.9%	-50.9%

Peer Comparisons for Bicycle Therapeutics

Financials

	BCYC	VRTX	ABBV	AMGN	GILD	REGN	Median
Name	Bicycle .	Vertex P.	AbbVie	Amgen	Gilead S.	Regenero.
Mkt Price	-	401.00	211.92	286.92	112.71	577.90	286.92
Mkt Cap	-	102.9	374.7	154.4	140.3	60.7	140.3
Rev LTM	-	11,419	58,328	34,917	28,862	14,214	28,862
Op Inc LTM	-	-199	13,695	8,192	10,797	3,841	8,192
FCF LTM	-	3,500	18,239	10,605	9,369	3,556	9,369
FCF 3Y Avg	-	1,984	20,273	8,590	8,397	3,248	8,397
CFO LTM	-	3,846	19,283	12,013	9,868	4,744	9,868
CFO 3Y Avg	-	2,324	21,154	9,753	8,949	4,518	8,949

Growth & Margins

	BCYC	VRTX	ABBV	AMGN	GILD	REGN	Median
Name	Bicycle .	Vertex P.	AbbVie	Amgen	Gilead S.	Regenero.
Rev Chg LTM	-	10.5%	6.1%	12.9%	3.8%	5.4%	6.1%
Rev Chg 3Y Avg	-	11.0%	0.6%	10.0%	1.6%	0.3%	1.6%
Rev Chg Q	-	12.1%	6.6%	9.4%	1.8%	3.6%	6.6%
QoQ Delta Rev Chg LTM	-	2.9%	1.7%	2.3%	0.4%	0.9%	1.7%
Op Mgn LTM	-	-1.7%	23.5%	23.5%	37.4%	27.0%	23.5%
Op Mgn 3Y Avg	-	26.5%	27.2%	26.4%	39.2%	30.1%	27.2%
QoQ Delta Op Mgn LTM	-	2.0%	1.0%	1.6%	-0.0%	-0.2%	1.0%
CFO/Rev LTM	-	33.7%	33.1%	34.4%	34.2%	33.4%	33.7%
CFO/Rev 3Y Avg	-	22.5%	37.5%	32.0%	31.9%	33.6%	32.0%
FCF/Rev LTM	-	30.6%	31.3%	30.4%	32.5%	25.0%	30.6%
FCF/Rev 3Y Avg	-	19.2%	36.0%	28.2%	30.0%	24.1%	28.2%

Valuation

	BCYC	VRTX	ABBV	AMGN	GILD	REGN	Median
Name	Bicycle .	Vertex P.	AbbVie	Amgen	Gilead S.	Regenero.
Mkt Cap	-	102.9	374.7	154.4	140.3	60.7	140.3
P/S	-	9.0	6.4	4.4	4.9	4.3	4.9
P/EBIT	-	23.4	63.6	14.9	17.1	12.4	17.1
P/E	-	28.3	99.6	23.3	22.2	13.6	23.3
P/CFO	-	26.8	19.4	12.8	14.2	12.8	14.2
Total Yield	-	3.5%	4.0%	7.5%	7.3%	7.6%	7.3%
Dividend Yield	-	0.0%	3.0%	3.2%	2.8%	0.3%	2.8%
FCF Yield 3Y Avg	-	2.1%	7.3%	6.2%	8.0%	4.4%	6.2%
D/E	-	0.0	0.2	0.4	0.2	0.0	0.2
Net D/E	-	-0.0	0.2	0.3	0.1	-0.1	0.1

Returns

	BCYC	VRTX	ABBV	AMGN	GILD	REGN	Median
Name	Bicycle .	Vertex P.	AbbVie	Amgen	Gilead S.	Regenero.
1M Rtn	-	-13.2%	8.6%	-2.6%	-0.4%	3.6%	-0.4%
3M Rtn	-	-10.2%	14.2%	-0.1%	3.8%	18.6%	3.8%
6M Rtn	-	-17.5%	3.8%	-6.5%	-0.4%	-14.2%	-6.5%
12M Rtn	-	-19.1%	11.8%	-11.2%	47.3%	-51.0%	-11.2%
3Y Rtn	-	42.7%	74.1%	30.3%	97.4%	-0.0%	42.7%
1M Excs Rtn	-	-16.1%	5.7%	-5.4%	-3.3%	0.7%	-3.3%
3M Excs Rtn	-	-18.1%	6.2%	-7.8%	-3.9%	9.8%	-3.9%
6M Excs Rtn	-	-26.7%	-7.7%	-15.8%	-11.1%	-25.0%	-15.8%
12M Excs Rtn	-	-32.8%	-2.4%	-24.7%	33.4%	-66.3%	-24.7%
3Y Excs Rtn	-	-15.1%	17.5%	-24.3%	45.4%	-56.7%	-15.1%

Financials

Annual
Quarterly

$ Mil \| FY: 12/31	LTM	2024	2023	2022	2021	2020	2019
Period End		12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020	12/31/2019
Filing Date		2/25/2025	2/20/2024	2/28/2023	3/1/2022	3/11/2021	3/10/2020
Key Financials
Total Revenue	19	35	27	14	12	10	14
Ebitda	-241	-165	-169	-107	-64	-50	-30
Operating Income	-288	-209	-189	-117	-66	-52	-26
Net Income	-242	-169	-181	-113	-67	-51	-31
EPS	-3.51	-2.90	-5.08	-3.80	-2.67	-2.66	-2.77
Growth Rates
Total Revenue Growth	-51.3%	30.8%	86.5%	23.6%	12.6%	-24.7%	93.4%
EBITDA Growth	-57.3%	2.7%	-58.0%	-67.3%	-28.2%	-67.2%	-38.9%
Operating Income Growth	-57.3%	-10.5%	-62.3%	-77.8%	-26.3%	-97.6%	-20.9%
Net Income Growth	-46.6%	6.4%	-60.3%	-68.7%	-31.0%	-66.7%	-40.1%
Margins
EBITDA Margin	-1249.0%	-467.4%	-628.0%	-741.3%	-547.9%	-481.2%	-216.7%
Operating Income Margin	-1493.5%	-592.9%	-701.9%	-806.6%	-561.0%	-500.1%	-190.6%
Net Income Margin	-1257.0%	-479.2%	-669.7%	-779.3%	-571.2%	-491.0%	-221.8%
Cash & Debt
Total Cash	721	880	526	339	439	136	92
Total Debt	7	9	45	44	44	16	2
Net Debt / (Cash)	-714	-870	-481	-295	-394	-120	-90
Cash Flows
Net Cash from Operations	-208	-165	-61	-86	-15	-18	-29
Free Cash from Operations	-210	-166	-64	-105	-17	-19	-30
Returns to Shareholders
Dividends	0	-0	-0	-0	-0	-0	-0
Share Repurchases	-0	-0	-0	-0	-0	-0	-0

$ Mil \| FY: 12/31	2025Q2	2025Q1	2024Q4	2024Q3	2024Q2	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3
Period End	6/30/2025	3/31/2025	12/31/2024	9/30/2024	6/30/2024	3/31/2024	12/31/2023	9/30/2023	6/30/2023	3/31/2023	12/31/2022	9/30/2022
Filing Date	8/8/2025	5/1/2025	2/25/2025	10/31/2024	8/6/2024	5/2/2024	2/20/2024	11/2/2023	8/3/2023	5/4/2023	2/28/2023	11/3/2022
Key Financials Quarterly
Total Revenue	3	10	4	3	9	20	5	5	11	5	3	3
Ebitda	-77	-60	-51	-52	-37	-24	-46	-45	-41	-37	-28	-27
Operating Income	-87	-70	-67	-64	-47	-32	-54	-50	-44	-41	-33	-30
Net Income	-79	-61	-52	-51	-40	-27	-49	-50	-43	-39	-30	-28
EPS	-1.14	-0.88	-0.75	-0.74	-0.77	-0.62	-1.16	-1.26	-1.41	-1.30	-1.01	-0.96
Key Financials TTM
Total Revenue TTM	19	26	35	37	40	42	27	25	23	15	14	15
Ebitda TTM	-241	-201	-165	-160	-153	-157	-169	-151	-133	-118	-107	-97
Operating Income TTM	-288	-247	-209	-196	-183	-180	-189	-168	-148	-131	-117	-102
Net Income TTM	-242	-203	-169	-166	-165	-168	-181	-162	-140	-124	-113	-101
Growth Rates Quarterly
Total Revenue Growth	-68.8%	-48.9%	-30.4%	-50.0%	-17.9%	298.9%	67.4%	76.1%	160.3%	26.8%	-15.5%	-29.8%
EBITDA Growth	-108.0%	-146.2%	-10.5%	-15.3%	8.4%	34.5%	-64.3%	-70.2%	-57.7%	-39.5%	-60.5%	-90.2%
Operating Income Growth	-86.8%	-120.2%	-23.3%	-26.8%	-7.5%	23.1%	-65.9%	-67.2%	-63.4%	-51.6%	-83.2%	-107.4%
Net Income Growth	-98.3%	-128.7%	-5.6%	-1.8%	6.6%	32.0%	-63.8%	-76.0%	-58.8%	-41.7%	-66.2%	-93.1%
Margins Quarterly
EBITDA Margin	-2651.8%	-602.9%	-1380.3%	-1944.9%	-397.7%	-125.1%	-868.6%	-843.1%	-356.7%	-762.2%	-885.0%	-871.8%
Operating Income Margin	-2991.3%	-701.7%	-1809.4%	-2374.0%	-499.4%	-162.8%	-1020.8%	-935.8%	-381.7%	-844.6%	-1030.0%	-985.5%
Net Income Margin	-2703.8%	-608.9%	-1398.4%	-1898.4%	-425.3%	-136.0%	-921.0%	-932.3%	-373.8%	-797.9%	-941.2%	-932.5%
Cash & Debt
Total Cash	721	793	880	891	961	457	526	572	340	294	339	361
Total Debt	7	8	9	11	43	44	45	46	47	49	44	44
Net Debt / (Cash)	-714	-785	-870	-880	-919	-413	-481	-526	-293	-244	-295	-317
Cash Flows Quarterly
FCF from Operations	-73	-86	-9	-40	-45	-71	-47	-1	34	-46	-30	-6
Cash Flows TTM
FCF from Operations TTM	-208	-180	-165	-203	-164	-85	-61	-44	-48	-106	-86	-66
Returns to Shareholders Quarterly
Dividends	0	0	0	0	0	0	0	0	0	0	0	0
Share Repurchases	-0	-0	-0	-0	-0	-0	-0	-0	-0	-0	-0	-0
Return on Invested Capital (ROIC) Quarterly
ROIC	-44.9%	-39.5%	-43.5%	-41.0%	-35.1%	-26.1%	-54.3%	-56.9%	-50.6%	-44.1%	-42.1%	-43.5%
Return on Invested Capital (ROIC) TTM
ROIC TTM	-36.3%	-34.5%	-33.7%	-33.2%	-34.3%	-37.4%	-47.2%	-47.6%	-42.9%	-34.9%	-37.5%	-36.6%

Segment Financials

Revenue by Segment

$ Mil	2024	2023	2022	2021	2020
Developing a unique class of chemically synthesized medicines based on its proprietary platform	27	14
AstraZeneca			1	3	2
Bayer			0
Dementia Discovery Fund			0	0	0
Genentech			6	5	0
Ionis			4	0
Novartis			0
Oxurion				2	0
Sanofi				0	11
Material transfer agreement					1
Total	27	14	12	10	14

Net Income by Segment

$ Mil	2024	2023	2022	2021	2020
Developing a unique class of chemically synthesized medicines based on its proprietary platform	-181	-113
Total	-181	-113

Price Behavior

Behavior Stats
Betas Matrix

Price Behavior

Market Price	$7.10
Market Cap ($ Bil)	0.5
First Trading Date	05/23/2019
Distance from 52W High	-74.2%
	50 Days	200 Days
DMA Price	$7.65	$10.86
DMA Trend	down	down
Distance from DMA	-7.2%	-34.6%
	3M	1YR
Volatility	44.8%	72.0%
Downside Capture	195.51	206.08
Upside Capture	18.83	66.81
Correlation (SPY)	28.8%	32.7%
	5D	10D
Expected Return	1.6%	0.8%
Expected Excess Return	-2.6%	-1.8%
Chance of Rise	44.0%	54.5%
Std Dev of Returns	3.3%	4.8%

BCYC Betas & Captures as of 8/31/2025

	1M	2M	3M	6M	1Y	3Y
Beta	0.93	1.70	1.33	1.18	1.20	0.95
Up Beta	-0.54	0.59	0.43	0.93	1.09	1.14
Down Beta	3.49	4.64	4.48	1.52	1.08	0.90
Up Capture	-29%	135%	29%	72%	57%	21%
Bmk +ve Days	10	22	35	71	142	415
Stock +ve Days	12	24	34	61	108	348
Down Capture	238%	144%	161%	143%	144%	103%
Bmk -ve Days	11	19	27	54	106	334
Stock -ve Days	9	17	28	64	140	401

[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively

Short Interest

Short Interest: As Of Date	8152025
Short Interest: Shares Quantity	1,645,537
Short Interest: % Change Since 7312025	-0.9%
Average Daily Volume	285,876
Days-to-Cover Short Interest	5.76
Basic Shares Quantity	69,252,009
Short % of Basic Shares	2.4%

Earnings Returns History

Expand for More

	Forward Returns
Earnings Date	1D Returns	5D Returns	21D Returns
8/8/2025	2.5%	-1.1%
2/25/2025	-1.3%	-6.9%	-21.3%
10/31/2024	-2.4%	-1.6%	-15.1%
8/6/2024	7.4%	1.5%	-9.3%
5/2/2024	2.0%	-2.4%	-8.3%
2/20/2024	0.8%	13.6%	9.1%
11/2/2023	-2.9%	-0.1%	-2.3%
7/13/2023	-0.2%	-3.7%	-14.3%
...
SUMMARY STATS
# Positive	9	6	7
# Negative	10	13	12
Median Positive	2.0%	4.7%	12.1%
Median Negative	-1.3%	-2.4%	-7.3%
Max Positive	21.3%	24.6%	38.4%
Max Negative	-3.7%	-11.4%	-21.3%

	Forward Returns
8/8/2025	2.5%	-1.1%
2/25/2025	-1.3%	-6.9%	-21.3%
10/31/2024	-2.4%	-1.6%	-15.1%
8/6/2024	7.4%	1.5%	-9.3%
5/2/2024	2.0%	-2.4%	-8.3%
2/20/2024	0.8%	13.6%	9.1%
11/2/2023	-2.9%	-0.1%	-2.3%
7/13/2023	-0.2%	-3.7%	-14.3%
2/28/2023	-2.0%	-6.8%	-3.4%
11/3/2022	-0.5%	6.2%	29.6%
8/4/2022	11.1%	24.6%	15.0%
3/1/2022	-0.4%	-11.4%	-7.3%
10/14/2021	-0.6%	-5.6%	-3.0%
8/5/2021	1.6%	-0.1%	38.4%
3/11/2021	-1.3%	3.2%	3.8%
11/5/2020	1.2%	0.3%	5.2%
8/5/2020	2.0%	-1.9%	12.1%
3/10/2020	21.3%	-9.6%	-5.3%
11/7/2019	-3.7%	-2.3%	-4.8%
SUMMARY STATS
# Positive	9	6	7
# Negative	10	13	12
Median Positive	2.0%	4.7%	12.1%
Median Negative	-1.3%	-2.4%	-7.3%
Max Positive	21.3%	24.6%	38.4%
Max Negative	-3.7%	-11.4%	-21.3%

SEC Filings

Expand for More

Report Date	Filing
6302025	10-Q 6/30/2025
3312025	10-Q 3/31/2025
12312024	10-K 12/31/2024
9302024	10-Q 9/30/2024
6302024	10-Q 6/30/2024
3312024	10-Q 3/31/2024
12312023	10-K 12/31/2023
9302023	10-Q 9/30/2023
6302023	10-Q 6/30/2023
3312023	10-Q 3/31/2023
12312022	10-K 12/31/2022
9302022	10-Q 9/30/2022
6302022	10-Q 6/30/2022
3312022	10-Q 3/31/2022
12312021	10-K 12/31/2021
9302021	10-Q 9/30/2021

Insider Activity

Expand for More

	Owner	Title	Filing Date	Action	Price	Shares	Transacted Value	Value of Held Shares	Form
0	Lee Kevin	CHIEF EXECUTIVE OFFICER	7072025	Sell	7.09	2,268	16,080	3,431,539	Form
1	Skynner Michael	CHIEF TECHNOLOGY OFFICER	7072025	Sell	7.09	825	5,849	858,209	Form
2	Milnes Alistair	CHIEF OPERATING OFFICER	7072025	Sell	7.09	1,149	8,146	683,958	Form
3	Hannay Michael Charles Ferguson	CHIEF PROD & SUPPLY CHAIN OFF	7072025	Sell	7.09	474	3,361	383,378	Form
4	Thompson Travis Alvin	CHIEF ACCOUNTING OFFICER	7072025	Sell	7.09	206	1,461	224,193	Form

Industry Resources

Health Care Resources

U.S. National Library of Medicine

Health Data Management

FDA Tracker

Biotechnology Resources

Fierce Biotech

Nature Biotechnology

Genetic Engineering & Biotechnology News

Biotechnology Innovation Organization

BioWorld

BioTechniques

HBS Biotechnology Publications

External Quote Links

0	Y Finance	Barrons
1	TradingView	Morningstar
2	SeekingAlpha	ValueLine
3	Motley Fool	Robinhood
4	CNBC	Etrade
5	MarketWatch	Unusual Whales
6	YCharts	Perplexity Finance
7	FinViz

Prefer one of these to Trefis? Tell us why.

Bicycle Therapeutics (BCYC)

Market Price (9/4/2025): $7.2 | Market Cap: $498.6 MilSector: Health Care | Industry: Biotechnology

Bicycle Therapeutics (BCYC)

Market Price (9/4/2025): $7.2Market Cap: $498.6 MilSector: Health CareIndustry: Biotechnology

Investment Highlights

Market Valuation

Stock Price Chart

Market Cap Chart

Business Description

Price Returns Compared

Interactive Breakdown

Better Bets than Bicycle Therapeutics (BCYC)

Latest Trefis Analyses

Recent Active Movers

1 Day Top Gainers

1 Day Top Losers

1 Week Top Gainers

1 Week Top Losers

1 Month Top Gainers

1 Month Top Losers

Recent Active Movers

1 Day Top Gainers

1 Day Top Losers

1 Week Top Gainers

1 Week Top Losers

More From Trefis

Research & Analysis

Invest in Strategies

Wealth Management

Peer Comparisons for Bicycle Therapeutics

Financials

Growth & Margins

Valuation

Returns

Comparison Analyses

FDIC Bank Data

Bank Capital

Bank Deposits

Bank Assets

Bank Loans

Financials

Segment Financials

Price Behavior

Short Interest

Returns Analyses

Earnings Returns History

SEC Filings

Insider Activity

Industry Resources

External Quote Links

Market Price (9/4/2025): $7.2 | Market Cap: $498.6 Mil
Sector: Health Care | Industry: Biotechnology

Market Price (9/4/2025): $7.2
Market Cap: $498.6 Mil
Sector: Health Care
Industry: Biotechnology